Follows Announcement Earlier this Week that Ampligen Co-Founder and Former AIM CEO Agreed to Join Scientific Advisory Board if Kellner…
Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat…
The south suburban Chicago home-like facility is expected to serve 500+ patients each yearCHICAGO, Dec. 12, 2024 (GLOBE NEWSWIRE) --…
A $29 entry price helps provide accessibility for people pursuing weight loss goalsService includes all features of Noom Med with…
Precede Bio’s ER dependency index (PERDI) tests for both ER dependent and ER independent mechanisms of cancer growth, addressing an…
BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…
- IMM-1-104 has the potential to benefit melanoma patients who have progressed on or are intolerant to immune checkpoint inhibitors…
Has helped over 24,400 Seniors Age Safely at Home Since Its InceptionDENVER, Dec. 12, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding…
DALLAS, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven…
Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients Both KB408 for AATD patients…